<Suppliers Price>

Corticosterone

Names

[ CAS No. ]:
50-22-6

[ Name ]:
Corticosterone

[Synonym ]:
Pregn-4-ene-3,20-dione, 11β,21-dihydroxy-
CORTICOSTERONE
Pregn-4-ene-3,20-dione, 11β, 21-dihydroxy-
Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11β)-
EINECS 200-019-6
4-Pregnene-11b,21-diol-3,20-dione
11b,21-Dihydroxy-4-pregnene-3,20-dione
MFCD00037715
(11β)-11,21-Dihydroxypregn-4-ene-3,20-dione
Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11-β)- (9CI)
11b,21-Dihydroxyprogesterone
(8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
(11b)-11,21-Dihydroxypregn-4-ene-3,20-dione
11b,21-Dihydroxypregn-4-ene-3,20-dione
Pregn-4-ene-3,20-dione, 11-β,21-dihydroxy-
4-08-00-02907 (Beilstein Handbook Reference)
4-Pregnene-11β,21-diol-3,20-dione

Biological Activity

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
529.2±50.0 °C at 760 mmHg

[ Melting Point ]:
179-183 °C(lit.)

[ Molecular Formula ]:
C21H30O4

[ Molecular Weight ]:
346.461

[ Flash Point ]:
288.0±26.6 °C

[ Exact Mass ]:
346.214417

[ PSA ]:
74.60000

[ LogP ]:
1.76

[ Vapour Pressure ]:
0.0±3.2 mmHg at 25°C

[ Index of Refraction ]:
1.576

[ Storage condition ]:
Store at RT

[ Stability ]:
Stable, but light sensitive. Incompatible with strong oxidizing agents.

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GM7650000
CHEMICAL NAME :
Corticosterone
CAS REGISTRY NUMBER :
50-22-6
BEILSTEIN REFERENCE NO. :
2339601
LAST UPDATED :
199703
DATA ITEMS CITED :
13
MOLECULAR FORMULA :
C21-H30-O4
MOLECULAR WEIGHT :
346.51
WISWESSER LINE NOTATION :
L E5 B666 OV MUTJ A1 CQ E1 FV1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
14 mg/kg
SEX/DURATION :
female 19-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
525 mg/kg
SEX/DURATION :
female 12-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 mg/kg
SEX/DURATION :
female 8-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
84 mg/kg
SEX/DURATION :
female 16-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1472 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
40 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
80 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Bird - chicken Embryo
DOSE/DURATION :
1500 pmol/L
REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H317

[ Precautionary Statements ]:
P280

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ Hazard Codes ]:
Xi,N,Xn,T

[ Risk Phrases ]:
R43

[ Safety Phrases ]:
S36

[ RIDADR ]:
2811.0

[ WGK Germany ]:
3

[ RTECS ]:
GM7650000

[ Hazard Class ]:
6.1

Synthetic Route

Precursor & DownStream

Articles

Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.

Br. J. Pharmacol. 172(3) , 857-68, (2015)

AT1 receptor blockers (ARBs) represent an approach for treating metabolic syndrome due to their potency in reducing hypertension, body weight and onset of type 2 diabetes. The mechanism underlying ARB...

Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice.

PLoS ONE 9(5) , e98398, (2014)

Osteopontin (OPN) is a multifunctional extracellular matrix (ECM) protein involved in multiple physiological processes. OPN expression is dramatically increased in visceral adipose tissue in obesity a...

Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia.

J. Appl. Physiol. 117(7) , 765-76, (2014)

Obstructive sleep apnea causes chronic intermittent hypoxia (IH) and is associated with impaired glucose metabolism, but mechanisms are unknown. Carotid bodies orchestrate physiological responses to h...


More Articles


Related Compounds